Search research articles
Contact Us
Filters
Showing results (1-10 of 76) with videos related to
Page
of 8
Sort By:
Biochimica Et Biophysica Acta
|
May 9, 2001
Centrosome abnormalities, genomic instability and carcinogenic progression
S Duensing, K Münger
Blood
|
April 1, 1995
Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia
S Duensing, J Atzpodien
Perception
|
January 1, 1979
The Cheshire Cat effect
S Duensing, B Miller
Oncology (Williston Park, N.Y.)
|
February 1, 1994
Are we obtaining the maximum benefit from GM-CSF and G-CSF?
S C Gulati, S Duensing
Cancer Investigation
|
January 1, 1994
Evaluating the benefit of purging in stem cell transplantation
S C Gulati, S Duensing
Cancer Biotherapy & Radiopharmaceuticals
|
June 1, 1997
Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivo
M Meffert, S Duensing, J Atzpodien
The New England Journal of Medicine
|
May 16, 1996
P-glycoprotein and multidrug resistance
S Duensing, A Ganser, J Atzpodien
Blood
|
June 15, 1994
CD39 as a novel marker of in vivo immune activation
S Duensing, H Kirshner, J Atzpodien
Anticancer Research
|
September 1, 1995
Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients
S Duensing, J Grosse, J Atzpodien
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2000
Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell lines
S Duensing, A Duensing, J Grosse, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 76) with videos related to
Sort By:
Page
of 8
Biochimica Et Biophysica Acta
|
May 9, 2001
Centrosome abnormalities, genomic instability and carcinogenic progression
S Duensing, K Münger
Blood
|
April 1, 1995
Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia
S Duensing, J Atzpodien
Perception
|
January 1, 1979
The Cheshire Cat effect
S Duensing, B Miller
Oncology (Williston Park, N.Y.)
|
February 1, 1994
Are we obtaining the maximum benefit from GM-CSF and G-CSF?
S C Gulati, S Duensing
Cancer Investigation
|
January 1, 1994
Evaluating the benefit of purging in stem cell transplantation
S C Gulati, S Duensing
Cancer Biotherapy & Radiopharmaceuticals
|
June 1, 1997
Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivo
M Meffert, S Duensing, J Atzpodien
The New England Journal of Medicine
|
May 16, 1996
P-glycoprotein and multidrug resistance
S Duensing, A Ganser, J Atzpodien
Blood
|
June 15, 1994
CD39 as a novel marker of in vivo immune activation
S Duensing, H Kirshner, J Atzpodien
Anticancer Research
|
September 1, 1995
Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients
S Duensing, J Grosse, J Atzpodien
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2000
Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell lines
S Duensing, A Duensing, J Grosse, et al.
Page
of 8